Antibody/XDC Schedule Launches! Full-Chain CMC & Regulatory Expertise Assembled | 2026BPD Chengdu

Antibody and XDC industries accelerate concentration in Chengdu and Southwest ChinaBaili Tianheng's global first bispecific ADC has received approval for market launch; Kelun-Biotech's TROP2 ADC continues to expand into new indications; WuXi Biologics' Chengdu base is expected to commence GMP production by the end of 2026.Scaling Conjugation Processes and Strengthening CMC Capabilities for Commercial Compliancewill be one of the core challenges for the region to transition from "molecular innovation" to "global delivery."

Against this backdrop,2026BPD Chengdu Biopharmaceutical Process Development Conferencewill be11 5-6InHyatt Place Chengdu Bio-CityPresented byYimao MedicalHostColbocelCo-organizeJingze Bio、Heibowei Pharmaceuticals、Excellence, Ever New、Vesijun BiologyInnovation partners confirmed! Gathering onsite.2000+Professional Buyers,70+Featuring distinguished speakers, the event offers a diverse lineup including technical forums, end-to-end exhibitions, and BPD Match sessions. Centered on technical presentations and case studies, it fosters CMC professional exchange, empowers emerging CMC talent, and builds an efficient platform focused on deep expertise to address real-world industry challenges.

Forum Highlights Preview

• Agenda-setting completeCovers the full CMC value chain—from ADC/XDC discovery, conjugation, downstream purification, and comparability studies to GMP compliance and commercial manufacturing—addressing critical pain points in technology development and commercial regulatory compliance.

• Live Session Speakers:Brings together frontline leaders from leading biopharma companies—including CJ TCI, Innovent Biologics, Kinseal Pharmaceutical, Henlius, and WuXi Biologics—as well as regulatory experts such as former NMPA GMP inspection team leaders.

• Integration of Cutting-Edge TechnologiesAI-powered CMC, intelligent automation discovery, and smart factory development, showcasing the deep integration of digitalization and biopharmaceutical processes.

• Regional Industrial Synergy:Addressing CMC capability bottlenecks in the Southwest region's transition from molecular innovation to global delivery of antibodies and ADCs through on-site sharing and collaboration to drive regional industry growth.
  

Antibody/XDC Conference Agenda

Report: Innovative Process Development for Complex Molecules

Guest: Wang Zhenyu, Senior Director, GEMCare

Report: Strategies for Developing High-Yield Cell Lines for Complex Molecules

Guest: Zhang Yu, Vice Director of Process Development, Sanjiu Guojian

Report: Generation of Stable Cell Lines

Guest: Chuangrui Biotech

Report: Fusion Protein Process Development and Adaptability Optimization

Guest: Huang Haiqiu, Vice Dean and Director of R&D, Jeku Biotech

Report: Downstream Process Development for ADCs (Provisional)

Guest: Sun Xiaoxing, Director of ADC Process Development at Sino-US BioPharmaceuticals (Kimera)

Report: Innovation Directions in Downstream Purification Chromatography Processes

Guest: Zhu Ying, Head of Downstream Process, Zhenge Biotechnology

Report: Comparative Study of ADC

Guest: Qu Yaocheng, Vice Director of Quality Control Department, Sinopharm Crosslink

Report: Key Considerations for ADC Special Quality Control Strategies, Hardware Facilities, and Workshop Layout (Draft)

Guest: Professor Park, former head of the Drug GMP Inspection Team at the National Medical Products Administration

Report: ADC Conjugation Process Development (Provisional)

Guest: Hongbin Song, Senior Director of ADC CMC at Innovent Biologics

Master Class: Key Control Points and Inspection Practices for Sterility Assurance of Biological Products Under the Revision of the Appendix on Sterile Drug Products (Provisional)

Guest: Hongyu Tan, a senior domestic pharmaceutical GMP expert and former core inspector at CFDI.

Report: Intelligent Automation Discovery Platform – Differentiated Discovery Strategies for Next-Generation ADC/XDC Drugs

Guest: Zhang Hongwei, Chief Information Officer and Managing Director of Beijing at Kede Pharma

Report: Pending

Guest: Ran Zhang, Beihe Kangcheng, Chief Regulatory Advisor

Report: CMC Compliance Strategy for FDA/EMA Submission (Draft)

Speaker: Chen Xiaorong, Head of Global CMC Regulatory Affairs at WuXi Biologics

Report: New Drug Clinical Application Direction

Guest: Chen Yangqi, Chengdu Xuyuan Biology, COO

Report: Segmented Contract Manufacturing of Biological Products (Provisional)

Guest: He Yanchao, Simcere Pharmaceutical Group, Head of Quality/Qualified Person

Report: Key Success Factors for Technology Transfer (Provisional)

Guest: Li Hongcheng, Director of Upstream Process Development, Sinopharm Jinke

Report: Key Elements and Best Practices for Pre-Market Commercial Manufacturing in Biopharmaceuticals

Guest: Yang Shiming, Director of Production, Chubb Bio

Report: AI-Enabled Biopharmaceutical CMC and Regulatory Considerations

Guest: Dongqiang Lin, Zhejiang University, Professor

Interview: Building Smart Factories

Guest: Zhang Hong, Senior Director of Digital Development Center for Human Drug Formulations, Qilu Pharmaceutical

Report: Digital Transformation of Biopharmaceutical Manufacturing: Practices and Insights from Henlius.

Guest: Wei Gong, General Manager of ADC Development and Clinical Manufacturing at MacroGenics

Report: Pending

Guest: Ye Junmin, Salubris, CSO

2026BPD Chengdu Forum Module

2026BPDChengdu Speaker Lineup

2026BPD Chengdu Partial Sponsors

BPD Biopharmaceutical Process Development Conference

2027 Annual Plan

BPD Biopharmaceutical Process Development Conference, is an industry-leading conference focused on the full lifecycle of biologic drug development, from process development to commercialization, since2017byYimao MedicalSince its inception, it has remained deeply committed to the CMC field and has become one of China's most influential annual events in biopharmaceutical CMC. In 2026, BPD Shanghai co-located with the AI FOR PHARMA Biopharmaceutical AI Summit, attracting over 7000 attendees.

2027，BPD adds a new coordinate，Seoul, South KoreaFirst-time inclusion in the BPD Global Conference series, officially completed.BPD Beijing - BPD USA - BPD Shanghai - BPD Singapore - BPD Seoul - BPD ChengduNew paradigm: Building a global CMC communication network for biopharmaceuticals, connecting worldwide innovation resources through process innovation to empower high-quality development of the global biopharma industry!